|
back
REFERENCES
1. Adolph L, Lorenz R.
Enzyme diagnosis in diseases of the heart, liver, and pancreas. New
York, S Karger Co., 1982,9-27.
2. Jung K, Mildner D, Jacob
B, et al. On the pyridoxal-5'-phosphate stimulation of AST and ALT in
serum and erythrocytes of patients undergoing chronic hemodialysis and
with kidney transplants. Clin Chim Acta 1981;115:105-110.
3. Wroblewski F. The clinical
significance of alterations in transaminase activities of serum and
other body fluids. Adv Clin Chem 1958;1:313-351.
4. Lott JA, Wolf PL. Alanine
and aspartate aminotransferase (ALT and AST). Clinical enzymology: a
case-oriented approach. Chicago, Year Book Medical Publishers, 1986,111-138.
5. Rej R. Measurement of
aminotransferases: Part 1. Aspartate aminotransferase. CRC Crit Rev
Clin Lab Sci 1984;21:99-106.
6. Price CP, Alberti KGMM:
Biochemical Assessment of Liver Function. in Wright R, Alberti KGMM,
Karran S, Millward-Sadler GH (eds.): Liver and Biliary Disease –
Pathophysiology, Diagnosis, Management. London: W.B. Saunders, 1979,381-416.
7. Panteghini M: Aspartate
aminotransferase isoenzymes. Clin Biochem 1990;23:311-319.
8. Siest G, Schiele F,
Galteau M-M, et al.: Aspartate aminotransferase and alanine aminotransferase
activities in plasma: statistical distributions, individual variations,
and reference values. Clin Chem 1975;21:1077-1087.
9. Manolio TA, Burke GL,
Savage PJ, et al.: Sex- and race-related differences in liver-associated
serum chemistry tests in young adults in the CARDIA study. Clin Chem
1992;28:1853-1859.
10. Salvaggio A, Periti M, Miano L, Tavanelli
M, Mazurati D: Body mass index and liver enzyme activity in serum. Clin
Chem 1991;37:720-723.
11. Nuttall FQ, Jones B:
Creatine kinase and glutamic oxolacetic transaminase activity in serum:
kinetics of change with exercise and effect of physical conditioning.
J Lab Clin Med 1968;51:257-261.
12. Dufour DR: Effects
of habitual exercise on routine laboratory tests. Clin Chem 1998;44:A136.
13. Zhou S-L, Gordon RE,
Bradbury M, Stump D, Kiang C-L, Berk PD: Ethanol up-regulates fatty
acid uptake and plasma membrane expression and export of mitochondrial
aspartate aminotransferase in Hep G-2 cells. Hepatology 1998;27:1064-1074.
13a. Litin S, O’Brien JF,
Pruett S, et al.: Macroenzyme as a cause of unexplained elevation of
aspartate aminotransferase. Mayo Clin Proc 1987;62:681-687.
13b. Mifflin TE, Bruns
DE, Wrotnoski U, et al.: Macroamylase, macro creatine kinase, and other
macroenzymes. Clin Chem 1985;31:1743-1748.
14. Bergmeyer HU, Scheibe
P, Wahlefeld AW. Optimization of methods for aspartate aminotransferase
and alanine aminotransferase. Clin Chem 1978;24:58-73.
15. Vanderlinde RE: Review
of pyridoxal phosphate and the transaminases in liver disease. Ann Clin
Lab Sci 1986;16:79-93.
16. Allman MA, Pang E,
Yau DF, Stewart PM, Tiller DJ, Truswell AS: Elevated plasma vitamers
of vitamin B6 in patients with chronic renal failure on regular hemodialysis.
Eur J Clin Nutr 1992;46:679-683.
17. AST and ALT. College
of American Pathologists, 325 Waukegan Road, Northfield, IL 60093, Chemistry
Survey 1997,15-18 (AST), 7-10 (ALT).
18. Posen S. Studies in human alkaline
phosphatases. M.D. thesis, University of Adelaide, Australia, 1966.
19. Posen S. Alkaline phosphatase.
Ann Intern Med 1967; 67:183-194.
20. Fishman WH, Ghosh NE.
Isoenzymes of human alkaline phosphatase. Adv Clin Chem 1976; 10:255-370.
21. Kaplan MM. Alkaline
phosphatase N Engl J Med 1972;62:452-468.
22. Crofton PM. Biochemistry
of alkaline phosphatase isoenzymes. Crit Rev Clin Lab Sci 1982;16:161-194.
23. McComb RB, Bowers GN
Jr, Posen S. Alkaline phosphatase. New York, Plenum Press, 1979;525-786.
24. Moss DW. Multiple forms
of acid and alkaline phosphatases: genetics, expression and tissue modification.
Clin Chim Acta 1986;161:123-135.
25. Weiss MJ, Ray K, Henthorn
PS, et al. Structure of the human liver/bone/kidney alkaline phosphatase
gene. J Biol Chem 1988;263:12002-12010.
26. Clubb JS, Neale FC,
Posen S. The behavior of infused placental alkaline phosphatase in human
subjects. J Lab Clin Med 1965;66:493-507.
27. Kleerekoper M, Horne
M, Cornish CJ, et al. Serum alkaline phosphatase after fat ingestion.
Clin Sci 1970;38:339-341.
28. Posen S, Grundstein
HS. Turnover of skeletal alkaline phosphatase in humans. Clin Chem 1982;28:153-154.
29. Dufour, DR: Gender
related differences in liver function and integrity tests. Clin Chem
1998;44:A137.
30. Bayer PM, Hotschek
H, Knoth E. Intestinal alkaline phosphatase and the ABO blood group
system: A new aspect. Clin Chim Acta 1980;108:81-7.
31. Dufour, DR: Effects
of oral contraceptives on routine laboratory tests. Clin Chem 1998;44:A137.
32. Moss DW. Physicochemical
and pathophysiological factors in the release of membrane-bound alkaline
phosphatase from cells. Clin Chim Acta 1997;257:133-140.
33. Schaeler R. The mechanism
of the increase in the activity of liver alkaline phosphatase in experimental
cholestasis: measurement of an increased enzyme concentration by immunochemical
titration. Z Klin Chem Klin Biochem 1975;13:277-281.
34. Schlaeger R, Haux D,
Kattermann R. Studies on the mechanism of the increase in serum alkaline
phosphatase activity in cholestasis: significance of the hepatic bile
acid concentration for the leakage of alkaline phosphatase from rat
liver. Enzyme 1982;28:3-13.
35. Epstein E, Kiechle
F, Zak B. Use of alkaline phosphatase isoenzymes analysis in the evaluation
of cholestatic liver disease. Ann Clin Lab Sci 1984;14:292-297.
36. Griffiths J. An alternate
origin for the placental isoenzyme of alkaline phosphatase. Arch Pathol
Lab Med 1992;116:1019-1024.
37. Bowers GN Jr, McComb
RB, Kelley ML. Measurement of total alkaline phosphatase activity in
human serum. Sel Meth Clin Chem 1977;8:31-9.
38. Bowers GN Jr, McComb
RB. Measurement of total alkaline phosphatase activity in human serum.
Clin Chem 1975;21:1988-1995.
39. Alkaline phosphatase.
College of American Pathologists, 325 Waukegan Road, Northfield, IL
60093, Chemistry Survey, 1997,11-14.
40. Gomez B, Ardakani S,
Ju J, et al. Monoclonal antibody assay for measuring bone-specific alkaline
phosphatase activity in serum. Clin Chem 1995;41:1551-1553.
41. Martin M, Van Hoof
V, Couttenye M, et al. Analytical and clinical evaluation of a method
to quantify bone alkaline phosphatase, a marker of osteoblastic activity.
Anticancer Res 1997;17:3167-3170.
42. Woitge HW, Seibel MJ,
Ziegler R. Comparison of total and bone-specific alkaline phosphatase
in patients with nonskeletal disorders or metabolic bone diseases. Clin
Chem 1996;42:1796-1804.
43. Chowdhury JR, Wolkoff
AW, Chowdhury NR, Arias IM. Hereditary jaundice and disorders of bilirubin
metabolism. In: The metabolic and molecular bases of inherited disease,
Scriver CR, Beaudet AL, Sly WS, Valle D, Stanbury JB, Wyngaarden JB,
Fredrickson DS, eds., New York, McGraw-Hill, Inc., 1995;2:2161-2208.
44. Berk PD, Noyer C. Clinical
chemistry and physiology of bilirubin. Sem Liver Dis 1994;14:346-351.
45. Bloomer JR, Berk PD,
Vergalla J, Berlin NI. Influence of albumin on the extravascular distribution
of unconjugated bilirubin. Clin Sci Mol Med 1973;45:517-521.
46. McDonagh AF, Palma
AA, Lauff JJ, Wu TW: Origin of mammalian biliprotein and rearrangement
of bilirubin glucuronides in vivo in the rat. J Clin Invest 1984;74:763-770.
47. Fevery J, Blanckaert
N: What can we learn from analysis of serum bilirubin. J Hepatol 1986;2:113-121.
48. Notter D. Bilirubin.
In: Interpretation of clinical laboratory tests, Siest G, Schiele F,
Henny J, Young DS, eds. Foster City, CA, Biomedical Publications, 1985,146-163.
49. Carmel R, Wong ET,
Weiner JM, Johson CS. Racial differences in serum total bilirubin levels
in health and in disease (pernicious anemia). JAMA 1985;253:3416-3418.
50. Dufour, DR: Effects
of food ingestion on routine laboratory tests. Clin Chem 1998;44:A136.
51. Van Hootegem P, Fevery
J, Blanckaert N: Serum bilirubins in hepatobiliary disease: comparison
with other liver function tests and changes in the portobstructive period.
Hepatology 1985;5:112-117.
52. Bosma PJ, Chowdhury
JR, Gantla BC, et al. The genetic basis of the reduced expression of
bilirubin UDP-glucuronosyltransferase 1 in Gilbert's Syndrome. N Engl
J Med 1995;333:1171-1175.
53. Thomsen HF, Hardt F,
Juhl E. Diagnosis of Gilbert's Syndrome. Scand J Gastroent 1981;16:699-703.
54. Lo DH, Wu TW: Assessment
of the fundamental accuracy of the Jendrassik-Grof total and direct
bilirubin assays. Clin Chem 1983;29:31-36.
55. ArvanD, Shirey TL:
Conjugated bilirubin: a better indicator of impaired hepatobiliary excretion
than direct bilirubin. Ann Clin Lab Sci 1984;15:252-259.
56. Doumas BT, Wu T-W,
Jendrzejcaz: Delta bilirubin: absorption spectra, molar absorptivity,
and reactivity in the diazo reaction. Clin Chem 1987;33:769-774
.
57. Doumas BT, Wu T-W.
The measurement of bilirubin fractions in serum. Crit Rev Clin Lab Sci
1991;28:415-446.
58. Ihara H, Shino Y, Hashizume
N, et al. Effect of light on total and direct bilirubin by an enzymatic
bilirubin oxidase method. J Anal Bio Sci 1997;20:349-354.
59. Kubasik NP, Mayer TK,
Bhaskar AG, Sine HE, D’Souza JP: The measurement of fractionated bilirubin
by Ektachem film slides – method validation and comparison of conjugated
bilirubin measurements with direct bilirubin in obstructive and hepatocellular
jaundice. Am J Clin Pathol 1985;84:518-523.
60. Total bilirubin. College
of American Pathologists, 325 Waukegan Road, Northfield, IL 60093, Chemistry
Survey 1997,18-20.
61. Binder L, Smith D,
Kupka T, et al.: Abnormalities of urine urobilinogen and urine bilirubin
assays and their relation to abnormal results of serum liver function
tests. South Med J 1988;81:1229-1232.
62. Binder L, Smith D,
Kupka T., et al.: Failure of prediction of liver function test abnormalities
with the urine urobilinogen and urine bilirubin assays. Arch Pathol
Lab Med 1989;.113:73-76.
63. Miura T, Matsuda Y,
Tsue A, et al. Immunological cross-reactivity of gamma-glutamyl transpeptidase
from human and rat kidney. J Biochem (Tokyo) 1981;89:217-222.
64. Tate SS, Meister A.
Gamma-glutamyl transpeptidase: catalytic, structural and functional
aspects. Mol Cell Biochem 1981; 39:357-368.
65. Jung K, Wischke UW.
Electrophoretic variants of alanine aminopeptidase, alkaline phosphatase,
and gamma-glutamyl transferase in urine. Clin Chem 1984;30:856-859.
66. Meister A, Anderson
ME. Glutathione. Ann Rev Biochem 1983;52:711-760.
67. Leino A, Impivaara
O, Irjala K, Maki J, Peltola O, Jarvisalo J: Health-based reference
intervals for ALAT, ASAT, and GT in serum, measured according to the
recommendations of the European Committee for Clinical Laboratory Standards
(ECCLS). Scand J Clin Lab Invest 1995;55:243-250.
68. Nilssen O, Helge-Forde
O, Brenn T: The Tromso study – distribution and population determinants
of gamma-glutamyltransferase. Am J Epidemiol 1990;132:318-326.
69. Schiele F. Guilmin
A-M, Detienne H, et al. Gamma-glutamyltransferase activity in plasma:
statistical distributions, individual variations, and reference intervals.
Clin Chem 1977;23:1023-1028.
69a. Combes B, Shore GM,
Cunningham FG, Walker FB, Shorey JW, Ware A: Serum gamma-glutamyl transpeptidase
activity in viral hepatitis: suppression in pregnancy and by birth control
pills. Gastroenterology 1977;72:271-274.
70. Aldenhovel HG: The
influence of long-term anticonvulsant therapy with diphenylhydantoin
and carbamazepine on serum gamma-glutamyltransferase, aspartate aminotransferase,
alanine aminotransferase and alkaline phosphatase. Eur Arch Psychiatry
Neurol Sci 1988;237:312-316.
71. Sheeman M, Maythorn
P. Predictive value of gamma-glutamyl transpeptidase in various liver
diseases. In: Goldberg DM, Werner M, eds. Progress in Clinical Enzymology,
New York, Masson, 1979,184-187.
72. Ratanasavanh D, Tazi
A, Gaspart E. Hepatic gamma-glutamyl transferase release: effect of
bile salt and membrane structure modification. Advan Biochem Pharamacol
1982;3:93-103.
72a. Anciaux ML, Pelletier
AG, Attali P, Meduri B, Liguory C, Etienne JP: Prospective study of
clinical and biochemical features of symptomatic choledocholithiasis.
Dig Dis Sci 1986;31:449-453.
72b. Itoh S, Nakajima M:
Liver gamma-glutamyl transferase activity in viral liver disease. Digestion
1986;33:121-125.
73. Schmidt E, Schmidt
FW: Progress in the enzyme diagnosis of liver disease: reality or illusion.
Clin Biochem 1990;23:375-283.
73a. Nemesanszky E, Lott
JA: Gamma-glutamyltransferase and its isoenzymes: progress and problems.
Clin Chem 1985;31:797-803.
73b. Betro MG. Oon RC,
Edwards JB: Gamma-glutamyl transpeptidase in diseases of the liver and
bone. Am J Clin Pathol 1973;60:672-678.
74. Kim NK, Yasmineh WG,
Freier EF, et al. Value of alkaline phosphatase, 5'-nucleotidase, gamma-glutamyltransferase,
and glutamate dehydrogenase activity measurements (single and combined)
in serum in diagnosis of metastasis to the liver. Clin Chem 1977;23:2034-2038.
75. Whitehead TP, Clarke
CA, Whitfield AGW: Biochemical and haematological markers of alcohol
intake. Lancet 1978;1:978-981.
76. Belfrage P, Berg B,
Hagerstrand I, Nilsson-Ehle P, Tornqvist H, Wiebe T: Alterations of
lipid metabolism in healthy volunteers during long-term ethanol intake.
Eur J Clin Invest 1977;127:127-131.
77. Moussavian SN, Becker
RC, Piepmeyer JL, Mezey E, Bozian RC: Serum gamma-glutamyl transpeptidase
and chronic alcoholism – influence of alcohol ingestion and liver disease.
Dig Dis Sci 1985;30:211-214.
78. Hedworth-Whitty RB,
Whitfield JB, Richardson RW. Serum gamma-glutamyltranspeptidase activity
in myocardial ischaemia. Brit Heart J 1967;29:432-438.
79. Goldberg DM. Functional and clinical
aspects of gamma-glutamyltranspeptidase and its isoenzymes: a critical
review of recent progress. In: Griffiths JC, Clinical enzymology, New
York, Masson Publishing USA, Inc., 1979,123-154.
79a. Burrows S, Feldman
W, McBride F: Serum gamma-glutamyl transpeptidase. Evaluation in screening
of hospitalized patients. Am J Clin Pathol 1975;64:311-314.
80. Shaw LM, Stromme JH,
London JL, Theodorsen L: International Federation of Clinical Chemistry.
Scientific Committee, Analytical Section. Expert Panel on Enzymes. IFCC
methods for measurement of enzymes. Part 4. IFCC methods for gamma-
glutamyltransferase [(gamma-glutamyl)-peptide: amino acid gamma- glutamyltransferase,
EC 2.3.2.2]. Clin Chim Acta 1983;135:315f-338f.
81. Gamma glutamyl transferase.
College of American Pathologists, 325 Waukegan Road, Northfield, IL
60093, Chemistry Survey 1997,33-34.
82. Ts’ao C, Swedlund J,
Neofotistos D: Implications of use of low international sensitivity
index thromboplastins in prothrombin time testing. Arch Pathol Lab Med
1994;118:1183-1187.
83. Peters RH, van den
Besselaar AMHP, Olthuis FM: Determination of the mean normal prothrombin
time for assessment of international normalized ratios. Usefulness of
lyophilized plasma. Thromb Haemost 1991;66:442-445.
84. WHO Expert Committee
on Biological Standardization. 33rd Report. World Health
Organ Tech Rep Ser 1983;687:81-105.
85. Taberner DA, Poller
L, Thomson JM, Darby KV: Effect of international sensitivity index (ISI)
of thromboplastins on precision of international normalised ratios (INR).
J Clin Pathol 1989:42:92-96.
86. Johnson M, Harrison
L, Moffatt K, Wilian A, Hirsh J: Reliability of the international normalized
ratio for monitoring the induction phase of warfarin: comparison with
the prothrombin time ratio. J Lab Clin Med 1996;128:214-217.
87. Kovacs MJ, Wong A,
MacKinnon K, et al.: Assessment of the validity of the INR system for
patients with liver impairment. Thromb Haemost 1994;71:727-730.
88. Robert A, Chazouilleres
O: Prothrombin time in liver failure: time, ratio, activity percentage,
or International Normalized Ratio? Hepatology 1996;24:1392-1394.
88a. Robert A, Chazouilleres
O: Prothrombin time in liver failureA: time, ratio, activity percentage,
or international normalized ratio? Hepatology 1996;24:1392-1394.
88b. Blanchard RA, Furie
BC, Jorgensen M, Kruger SF, Furie B: Acquired vitamin K-dependent carboxylation
deficiency in liver disease. N Engl J Med 1981;305:242-248.
89. Van den Besselaar AMHP,
Halem-Visser LP, Loeliger EA: The use of evacuated tubes for blood collection
in oral anticoagulant control. Thromb Haemost 1983;40:676-677.
90. Raskob GE, Durica SS.
Owen WL, Comp PC: Monitoring low-dose warfarin therapy by a central
laboratory and implications for clinical trials and patient care: the
Coumadin Aspirin Reinfarctin (CARS) Pilot Study Group. Am J Cardiol
1996;78:1074-1076.
91. Baglin T, Luddington
R: Reliability of delayed INR determination: implications for decentralized
anticoagulant care with off-site blood sampling. Br. J. Haematol 1997;96:431-434.
92. Fairweather RB, Ansell
J, van den Besselaar AMHP, et al.: College of American Pathologists
conference XXXI on laboratory monitoring of anticoagulant therapy –
laboratory monitoring of oral anticoagulant therapy. Arch Pathol Lab
Med 1998;122:768-781.
93. Dwyre AL, Giles AR,
Key LA, Butler JR, Beck LR, Callahan JB: The effects of sodium citrate
anticoagulant concentration, storage on or off cellular matrix, and
specimen age on prothrombin time INR using a low ISI (1.06) rabbit brain
thromboplastin. Thromb Haemost 1995;73:1237.
94. Adcock DM, Kressen
DC, Marlar RA: Effect of 3.2% vs. 3.8% sodium citrate on routine coagulation
testing. Am J Clin Pathol 1997;107:105-110.
95. Dufour, DR, Teot, L:
Laboratory identification of ischemic hepatitis (shock liver). Clin
Chem 34: 1287, 1988.
96. Fuchs S, Bogomolski-Yahalom
V, Paltiel O, Ackerman Z: Ischemic hepatitis: clinical and laboratory
observations of 34 patients. J Clin Gastroenterol 1998;26:183-186.
97. Singer AJ, Carracio
TR, Mofenson HC: The temporal profile of increased transaminase levels
in patients with acetaminophen-induced liver dysfunction. Ann Emerg
Med 1995;26:49-53.
98. Willner IR, Uhl MD,
Howard SC, Williams EQ, Riely CA, Waters B: Serious hepatitis A: an
analysis of patients hospitalized during an epidemic in the United States.
Ann Intern Med 1998;128:111-114.
99. Mendenhall CL and the
VA Cooperative Study Group on Alcoholic Hepatitis: Alcoholic hepatitis.
Clin Gastroenterol 1981;10:417-441.
100. O’Grady JG, Alexander
GJM, Hayllar KM, Williams R: Early indicators of prognosis in fulminant
hepatic failure. Gastroenterology 1989;97:4439-4445.
101. Bonacini M, Hadi G,
Govindarajan S, Lindsay KL: Utility of a discriminant score for diagnosing
advanced fibrosis or cirrhosis in patients with chronic hepatitis C
infection. Am J Gastroneterol 1997;92:1302-1304.
102. Poller L, Triplett
DA, Hirsh J, Carroll J, Clarke K: The value of plasma calibrants in
correcting coagulometer effects on international normalized ratios –
an international multicenter study. Am J Clin Pathol 1995;103:358-365.
103. Davis KD, Danielson
CFM, May LS, Han Z-Q: Use of different thromboplastin reagents causes
greater variability in international normalized ratio results than prolonged
room temperature storage of specimens. Arch Pathol Lab Med 1998;122:972-977.
104. Cunningham MTA, Johnson
GF, Pennell BJ, Olson JD: The reliability of manufacturer-determined,
instrument specific international sensitivity index values for calculating
the international normalized ratio. Am J Clin Pathol 1994;102:128-133.
105. Stevenson KJ, Craig
S, Dufty JMK, Taberner DA: System ISI calibration: a universally applicable
scheme is possible only when coumarin plasma calibrants are used. Br
J Haematol 1997;96:435-441.
106. Taberner DA, Poller
L, Thompson JM, Darby KV: Effect of international sensitivity index
(ISI) of thromboplastins on precision of international normalized ratios
(INR). J Clin Pathol 1989;42:92-96.
107. Kitchen S, Walker
ID, Woods TAL, Preston FE: Thromboplastin related differences in the
determination of international normalized ratio: a cause for concern?
Thromb Haemost 1994;72:426-429.
108. Lassen JF, Kjeldsen
J, Antonsen S, Petersen PH, Brandslund I: Interpretation of serial measurements
of international normalized ratio for prothrombin times in monitoring
oral anticoagulant therapy. Clin Chem 1995;41:1171-1176.
109. Poller L: Screening
INR deviation of local prothrombin time systems. J Clin Pathol 1998;51:356-359.
110. Johnson M, Brigder
M: A cross-Canada survey of prothrombin time testing – does the establishment
of local ISI values improve the accuracy of International Normalized
Ratio reporting? Am J Clin Pathol 1998;110:683-690.
110a. Stapleton JT: Host
immune response to hepatitis A virus. J Infect Dis 1995;175(Suppl 1):S9-S14.
111. Lemon SM, Brown CD,
Brooks DS, Simms TE, Bancroft WH: Specific immunoglobulin M response
to hepatitis A virus determined by solid phase radioimmunoassay. Infect
Immun 1980;28:927-936.
112. Koff RS: Seroepidemiology
of hepatitis A in the United States. J Infect Dis 1995;171(Suppl 1):S19-S23.
112a. Jilg W, Bittner R,
Bock HL, et al.: Vaccination against hepatitis A: comparison of different
short-term immunization schedules. Vaccine 1992;10(Suppl 1): S126-S128.
112b. Goubau P, Gan Gerven
V, Safary A: Effect of virus strain and antigen dose on immunogenicity
and reactogenicity of an inactivated hepatitis A vaccine. Vaccine 1992;10(Suppl
1):S114-S118.
112c. Totos G, Gizaris
V, Papaevangelou G: Hepatitis A vaccine: persistence of antibodies 5
years after the first vaccination. Vaccine 1997;15:1252-1253.
113. Feinstone SM, Kapikian
AZ, Purcell RH: Hepatitis A: detection by immune electron microscopy
of virus-like antigen associated with acute illness. Science 1973;182:1026-1028.
114. Hollinger FB, Bradley
DW, Maynard JE, Dreesman GR, Melnick JL: Detection of hepatitis A viral
antigen by radioimmunoassay. J Immunol 1975;115:1464-1466.
115. Fujiwara K, Yokosuka
O, Ehata T, et al.: Frequent detection of hepatitis A viral RNA in serum
during the early convalescent phase of acute hepatitis A. Hepatology
1997;26:1634-1649.
116. Hollinger FB, Dreesman
GR: Hepatitis viruses. In Rose NR, de Macario EC, Folds JD, Lane HC,
Nakamura RM (eds.): Manual of Clinical Laboratory Immunology,
5th ed. Washington DC, American Society for Microbiology,
1997
117. Lemon SM, Gates NL,
Simms TE, Bancroft WH: IgM antibody to hepatitis B core antigen as a
diagnostic parameter of acute infection with hepatitis B virus. J Infect
Dis 1981;143:803-809.
118. Noskin GA: Prevention,
diagnosis, and management of viral hepatitis: a guide for primary care
physicians. Arch Fam Med 1995;4:923-934.
119. Czaja AJ, Shiels MT,
Taswell HF, Wood JR, Ludwig J, Chase RC: Frequency and significance
of immunoglobulin M antibody to hepatitis B core antigen in corticosteroid-treated
severe chronic active hepatitis B. Mayo Clin Proc 1988;63:119-125.
120. Sjogren M, Hoofnagle
JH: Immunoglobulin M antibody to hepatitis B core antigen in patients
with chronic type B hepatitis. Gastroenterology 1985;89:252-258.
121. Seeff LB, Beebe GW,
Hoofnagle JH, et al.: A serologic follow-up of the 1942 epidemic of
post-vaccination hepatitis in the United States Army. N Engl J Med 1987;316:965-970.
121a. Aoki SK, Finegold
D, Kuramoto IK, et al.: Significance of antibody to hepatitis B core
antiben in blood donors as determined by their serologic response to
hepatitis B vaccine. Transfusion 1993;33:362-367.
121b. Draelos M, Morgan
T, Schifman RB, Sampliner RE: Significance of isolated antibody to hepatitis
B core antigen determined by immune response to hepatitis B vaccination.
JAMA 1987;258:1193-1195.
122. Yostuyanagi H, Yasuda
K, Iino S, et al.: Persistent viremia after recovery from self-limited
acute hepatitis B. Hepatology 1998;27:1377-1382.
123. Cabrerizo M, Bartolome
J, De Sequera P, Caramelo C, Carreno V: Hepatitis B virus DNA in serum
and blood cells of hepatitis B surface antigen-negative hemodialysis
patients and staff. J Am Soc Nephrol 1997;8:1443-1447.
124. Loriot MA, Marcellin
P, Walker F, et al.: Persistence of hepatitis B virus DNA in serum and
liver from patients with chronic hepatitis B after loss of HBsAg. J
Hepatol 1997;27:251-258.
125. Kuhns MC, McNamara
AL, Perrrilo RP, Cabal CM, Campbell CR: Quantitation of hepatitis B
viral DNA by solution hybridization: comparison with DNA polymerase
and hepatitis B e antigen during antiviral therapy. J Med Virol 1989;27:274-281.
126. Butterworth LA, Prior
SL, Buda PJ, Faoagali JL, Cooksley WG: Comparison of four methods for
quantitative measurement of hepatitis B viral DNA. J Hepatol 1996;24:
686-691.
128. Zaaijer HL, ter Borg
F, Cuypers HT, Hermus MC, Lelie PN: Comparison of methods for detection
of hepatitis B virus DNA. J. Clin. Microbiol. 1994;32:2088-2091.
129. Kaneko S, Miller RH,
Feinstone SM, et al.: Detection of serum hepatitis B virus DNA in patients
with chronic hepatitis using the polymerase chain reaction assay. Proc
Natl Acad Sci USA 1989;86:312-316.
130. Kessler HH, Pierer
K, Dragon E, et al.: Evaluation of a new assay for HBV DNA quantitation
in patients with chronic hepatitis B. Clin Diagn Virol 1998;9:37-43.
131. Chernesky MA, Gretch
D, Mushahwar IK, Swenson PD, Yarbough PO: Cumitech 18A. Laboratory diagnosis
of the hepatitis viruses. Coordinating ed. S. Young. Washington DC,
American Society for Microbiology, 1998.
132. Alter JH: New kit
on the block: evaluation of second-generation assays for detection of
antibody to the hepatitis C virus. Hepatology 1992;15:340-353.
133. Brillanti S: Serum
IgM antibodies to hepatitis C virus in acute and chronic hepatitis C.
Arch Virol Suppl 1993;8:213-218.
134. Aach R, Stevens C,
Hollinger F, et al.: Hepatitis C virus infection in post-transfusion
hepatitis. An analysis with first- and second-generation assays. N Engl
J Med 1991;325:1325-1329.
135. Barrera JM, Francis
B, Ercilla G, et al.: Improved detection of anti-HCV in post-transfusion
hepatitis by a third-generation ELISA. Vox Sang 1995;68:15-18.
136. Uyttendaele S, Claeys
H, Mertens W, Verhaert H, Vermylen C: Evaluation of third-generation
screening and confirmatory assays for HCV antibodies. Vox Sang 1994;66:15-18.
137. Busch M, Tobler L,
Quan S, et al.: A pattern of 5-1-1 and c100-3 only on hepatitis C (HCV)
recombinant immunoblot assay does not reflect HCV infection in blood
donors. Transfusion 1993;33:84-88.
138. Rossini A, Gazzola
GB, Ravaggi A, et al.: Long-term follow-up and infectivity in blood
donors with hepatitis C antibodies and persistently normal alanine aminotransferase
levels. Transfusion 1995;35:108-111.
139. Pawlotsky J, Bastie
A, Pellet C, et al.: Significance of indeterminate third-generation
hepatititis C virus recombinant immunoblot assay. J Clin Microbiol 1996;34:80-83.
139a. Villano SA, Vlahov
D, Nelson KE, Cohn S, Thomas DL: Persistence of viremia and the importance
of long-term follow-up after acute hepatitis C infection. Hepatology
1999;29:908-914.
140. Gretch D: Diagnostic
tests for hepatitis C. Hepatology 1997;26(Suppl 1): 43S-47S.
140a. Alter MJ, Margolis
HS, Krawczynski K, et al.: The natural history of community acquired
hepatitis C in the United States. N Engl J Med 1992;327:1899-1905.
141. Gretch DR, dela Rosa
C, Carithers RL, Wilson RA, Williams B, Corey L. Assessment of hepatitis
C viremia using molecular amplification technologies: correlations and
clinical implications. Ann Intern Med 1995;123:3211-329.
142. Barrera JM, Bruguera
M, Ercilla MG, et al.: Persistent hepatitis C viremia after acute self-limited
posttransfusion hepatitis. Hepatology 1995;21:639-644.
143. Damen M, Cuypers HTM,
Zaaijer HL, et al.: International collaborative study on the second
EUROHEP HCV-RNA reference panel. J Virol Meth 1995;48:175-185.
143a. Ravaggi A, Biasin
MR, Infantolino D, Cariani E: Comparison of competitive and non-competitive
reverse transcriptiohn-polymerase chain reaction (RT-PCR) for the quantification
of hepatitis C virus (HCV) RNA. J Virol Methods 1997;65A:123-129.
143b. Lunel et al. Hepatology
1999;29:528-535.
144. National Committee
for Clinical Laboratory Standards. Molecular Diagnostic Methods for
Infectious Diseases (MM3-A); Approved Guideline. Wayne PA, National
Committee for Clinical Laboratory Standards, 1995.
145. Davis GL, Lau JY,.
Urdea MS, et al.: Quantitative detection of hepatitis C virus RNA with
a solid-phase signal amplification assay: definition of optimal conditions
for specimen collection and clinical application in interferon-treated
patients. Hepatology 1994;19:1337-41.
146. Roth WK, Lee J-H,
Ruster B, Zeuzem S: Comparison of two quantitative hepatitis C virus
reverse transcriptase PCR assays. J Clin Microbiol 1996;34:261-264.
147. Lau JY, Mizokami M,
Kolberg JA, et al.: Application of six hepatitis C genotyping systems
to sera from chronic hepatitis C patients in the United States. J Infect
Dis 1995;171:282-289.
148. Rizetto M, Ponzetto
A, Forzani I: Epidemiology of hepatitis delta virus: overview. Prog
Clin Biol Res 1991;364:1-20.
149. Dinolfo L, Abate ML,
Bertolo P, et al.: Detection of hepatitis D virus RNA in serum by a
reverse transcription, polymerase chain reaction-based assay. Int J
Clin Lab Res 1995;25:35-39.
150. Madejon A, Cotonat
T, Bartolome J, Castillo I, Carreno V: Treatment of chronic hepatitis
D infection with low and high doses of interferon-alpha 2a: utility
of polymerase chain reaction in monitoring antiviral response. Hepatology
1994;19:1331-1336.
151. Polish LB, Gallagher
M, Fields HA, Hadler SC: Delta hepatitis: molecular biology and clinical
and epidemiological features. Clin Microbiol Rev 1993;6:211-229.
152. Yarbourgh, PO, Tam
AW, Gabor K, et al.: Assay development of diagnostic tests for hepatitis
E. In Nishioka K, Suzuki H, Mishiro S, Oda T (eds.): Viral Hepatitis
and Liver Disease. Tokyo, Japan, Springer-Verlag, 1994.
153. Mast EE, Alter MJ,
Holland PV, Purcell RH: Evaluation of assays for antibody to hepatitis
E virus by a serum panel. Hepatitis E Virus Antibody Serum Panel Evaluation
Group. Hepatology 1998;27:857-861.
154. Thomas DL, Yarbough
PO, Vlahov D, et al.: Seroreactivity to hepatitis E virus in areas where
the disease is not endemic. J Clin Microbiol 1997;35:1244-1247.
155. Gouvea V, Cohen SJ,
Santos N, Myint KS, Hoke C, Innis BL: Identification of hepatitis E
virus in clinical specimens: amplification of hydroxyapatite-purified
virus RNA and restriction endonuclease analysis. J Virol Methods 1997;69:53-61.
156. Clayson ET, Myint
KS, Snitbhan R, et al.: Viremia, fecal shedding, and IgM and IgG responses
in patients with hepatitis E. J Infect Dis 1995;172:927-933.
157. Chobe LP, Cdhadha
MS, Banerjee K, Arankalle VA: Detection of HEV RNA in faeces, by RT-PCR
during the epidemics of hepatitis E in India (1976-1995). J Viral Hepat
1997;4:129-133.
160. Ellis G, Goldberg
DM, Spooner RJ, Ward AM: Serum enzyme tests in diseases of the liver
and biliary tree. Am J Clin Pathol 1978;70:248-258.
160a. Fortson WC, Tedesco
FJ, Starnes EC, Shaw CT: Marked elevation of serum transaminase activity
associated with extrahepatic biliary tract disease. J Clin Gastroenterol
1985;7:502-505.
161. Borsch G, Baier J,
Glocke M, Nathusius W, Gerhardt W: Graphical analysis of laboratory
data in the differential diagnosis of cholestasis: a computer-assisted
prospective study. J Clin Chem Clin Biochem 1988;26:509-519.
162. Rozen P, Korn RJ,
Zimmerman HJ: Computer analysis of liver function tests and their interrelationship
in 347 cases of viral hepatitis. Isr J Med Sci 1970;6:67-79.
162a. Mendenhall CL and
the VA Cooperative Study Group on Alcoholic Hepatitis: Alcoholic hepatitis.
Clin Gastroenterol 1981;10:417-441.
162b. Mihas AA, Doos WG,
Spenney JG: Alcoholic hepatitis – a clinical and pathological study
of 142 cases. J Chronic Dis 1978;31:461-472.
162c. Goldberg S, Mendenhall
C, Anderson S, et al.: VA Cooperative Study on Alcoholic Hepatitis.
IV. The significance of clinically mild alcoholic hepatitis – describing
the population with minimal hyperbilirubinemia. Am J Gastroenterol 1986;81:1029-1034.
162d. Nissenbaum M, Chedid
A, Mendenhall C, Gartside P: Prognostic significance of cholestatic
alcoholic hepatitis. VA Cooperative Study Group # 119. Dig Dis Sci 1990;35:891-896.
163. Cohen JA, Kaplan MM:
The SGOT/SGPT ratio – an indicator of alcoholic liver disease. Dig Dis
Sci 1979;24:835-838.
163a. Stewart JS, Farrow
LJ, Clifford RE, et al.: A three-year survey of viral hepatitis in West
London. Q J Med 1978;47:365-84.
164. Lednar WM, Lemon SM,
Kirkpatrick JW, Redfield RR, Fields ML, Kelley PW: Frequency of illness
associated with epidemic hepatitis A virus infections in adults. Am
J Epidemiol 1985;122:226-233.
165. Gitlin N: Hepatitis
B: diagnosis, prevention, and treatment. Clin Chem 1997;43:1500-1506.
165a. McMahon BJ, Alward
WL, Hall DB, et al.: Acute hepatitis B virus infection: relation of
age to the clinical expression of disease and subsequent development
of the carrier state. J Infect Dise 1985;151:599-603.
166. Hoofnagel JH: Hepatitis
C: the clinical spectrum of disease. Hepatology 1997;26(Suppl 1):15S-20S.
167. Seeff LB, Wright EC,
Zimmerman HJ, McCollum: VA Cooperative study of post-transfusion hepatitis,
1969-1974: incidence and characteristics of hepatitis and responsible
risk factors. Am J Med Sci 1975;270:355-362.
167a. Harrison PM, O’Grady
JG, Keays RT, Alexander GJ, Williams R: Serial prothrombin time as prognostic
indicator in paracetamol induced fulminant hepatic failure. BMJ 1990;301:964-968.
168. Gitlin N, Serio KM:
Ischemic hepatitis: widening horizons. Am J Gastroenterol 1992;87:831-836.
169. Tygstrup N, Ranek
L: Assessment of prognosis in fulminant hepatic failure. Semin Liv Dis
1986;6:129-137.
170. Anand A, Nightingale
P, Neuberger P: Early indicators of prognosis in fulminant hepatic failure:
an assessment of the King’s criteria. J Hepatol 1997;26:62-68.
171. Harrison PRm O’Grady
JG, Keays RT, Alexander GJ, Williams R: Serial prothrombin time as prognostic
indicator in paracetamol induced fulminant hepatic failure. BMJ 1990;301:964-966.
172. Dymock IW, Tucker
JS, Woolf IL, et al: Coagulation studies as a prognostic index in acute
liver failure. Br J Haematol 1975;29:385-395.
173. Horak W, Waldram R,
Murray-Lyons IM, et al.: Kinetics of (14C) cholic acid in
fluminant hepatic failure: a prognostic test. Gastroenterology 1976;71:809-813.
173a. O’Grady JG, Alexander
GJM, Hayllar KM, Williams R: Early indicators of prognosis in fulminant
hepatic failure. Gastroenterology 1989;97:439-445.
173b. Munoz SJ: Prothrombin
time in fulminant hepatic faliure. Gastroenterology 1991;100:1480-1481.
174. London WT, Evans AA:
The epidemiology of hepatitis viruses B, C, and D. Clin Lab Med 1996;16:251-171.
175. Fry SW, Seeff LB:
Hepatotoxicity of analgesics and antiinflammatory agents. Gastroenterol
Clin North Am 1995;24:875-905.
176. Zimmerman HJ, Maddrey
WC: Acetaminophen (paracetamol) hepatotoxicity with regular intake of
alcohol: analysis of instances of therapeutic misadventure. Hepatology
1995;22:767-773.
176a. Silva MO, Roth D,
Reddy KR, Fernandez JA, Albores-Saavedra J, Schiff ER: Hepatic dysfunction
accompanying acute cocaine intoxication. J Hepatol 1991;12:312-315.
177. Johnson RD, O’Connor
ML, Kerr RM: Extreme serum elevations of aspartate aminotransferase.
Am J Gastroenterol 1995;90:1244-1245.
178. Shilsky ML: Wilson
disease: genetic basis of copper toxicity and natural history. Semin
Liv Dis 1996;16:83-95.
179. Steindl, P, Ferenci
P, Dienes HP, et al.: Wilson’s disease in patients presenting with liver
disease: a diagnostic challenge. Gastroenterology 1997;113:212-218.
180. Berman DH, Leventhal
RI, Gavaler JS, Cadoff EM, Van Thiel DH: Clinical differentiation of
fulminant Wilsonian hepatitis from other causes of hepatic failure.
Gastroenterology 1991;100:1129-1134.
181. Bull PC, Thomas GR,
Rommens JM, Forbes JR, Cox DW: The Wilson disease gene is a putative
copper transporting P-type ATP-ase similar to the Menkes gene. Nature
Genet 1993;5:327-337.
182. Thomas GR, Forbes
JR, Roberts EA, Walshe JM, Cox DW: The Wilson disease gene: spectrum
of mutations and their consequences. Nature Genet 1995;9:210-217.
183. Crapper RM, Bhathal
PS, Mackay IR, Frazer IH: "Acute" autoimmune hepatitis. Digestion
1986;34:216-225.
184. Amontree JS, Stuart
TD, Bredfeldt JE: Autoimmune chronic active hepatitis masquerading as
acute hepatitis. J Clin Gastroenterol 1989;11:303-307.
185. Davis GL, Czaja AJ,
Baggenstoss AH, Taswell HF: Prognostic and therapeutic implications
of extreme aminotransferase elevation in chronic hepatitis. Mayo Clin
Proc 1982;57:303-309.
186. Johnson PJ, McFarlane
IG, Alvarez F, et al.: Meeting report: International Autoimmune Hepatitis
Group. Hepatology 1993;18:998-1008.
187. Czaja AJ: Diagnosis
and therapy of autoimmune liver disease. Med Clin North Am 1996;80:973-994.
187aa. Horwitz CA, Burke
MD, Grimes P, Tombers J: Hepatic function in mononucleosis induced by
Epstein-Barr virus and cytomegalovirus. Clin Chem 1980;26:243-246.
187a. Liaw YF, Chu CM,
Su IJ, Huang MJ, Lin DY, Chang-Chien CS: Clinical and histological events
preceding hepatitis B e antigen seroconversion in chronic type B hepatitis.
Gastroenterology 1983;84:216-219.
187b. Yuki N, Hayashi N,
Moribe T, et al.: Relation of disease activity during chronic hepatitis
C infection to complexity of hypervariable region 1 quasispecies. Hepatology
1997;25:439-444.
188. Clermont RJ, Chalmers
TC: The transaminase tests in liver disease. Medicine 1967;46:197-207.
189. Scheig R: Evaluation
of tests used to screen patients with liver disorders. Prim Care 1996;23:551-60.
190. Tong MJ, el-Farra
NS, Crew MI: Clinical manifestations of hepatitis A. Recent experience
in a community teaching hospital. J Infect Dis 1995;171 Suppl 1:S15-S18.
190a. Sjogren MH, Tanno
H, Foy O, et al.: Hepatitis A virus in stool during clinical relapse.
Ann Intern Med 1987;106:221-226.
190b. Glikson M, Aalun
E, Oren R, Tur-Kapsa R, Shouval D: Relapsing hepatitis A: review of
14 cases and literature survey. Medicine 1992;71:140-23.
190c. Inglesby TV, Rai
R, Astemborski J, et al.: A prospective community-based evaluation of
liver enzymes in individuals with hepatitis C after drug use. Hepatology
1999;29:590-596.
191. Weiss JS, Gautman
A, Lauff JJ, et al.: The clinical importance of a protein-bound fraction
of serum bilirubin in patients with hyperbilirubinemia. N Engl J Med
1983;309:147-150.
192. Van Hootegem P, Fevery
J, Blanckaert N: Serum bilirubins in hepatobiliary disease: comparison
with other liver function tests and changes in the postobstructive period.
Hepatology 1985;5:112-117.
193. Adachi Y, Inufusa
H, Yamashita M, et al.: Serum bilirubin fractionation using multilayer
film method in hepatobiliary diseases in comparison with high performance
liquid chromatography. Gastroenterol Jpn 1987;22:633-639.
193a. Gordon SC, Reddy
KR, Schiff L, Schiff ER: Prolonged intrahepatic cholestasis secondary
to acute hepatitis A. Ann Intern Med 1984;101:635-637.
194. Poynard T, Bedossa
P, Opolon P: Natural history of liver fibrosis progression in patients
with chronic hepatitis C. Lancet 1997;349:825-832.
195. Niederau C, Lange
S, Heintges T, et al.: Prognosis of chronic hepatitis C: results of
a large prospective cohort study. Hepatology 1998;28:1687-1695.
196. Seeff LB: Natural
history of hepatitis C. Hepatology 1997;26(Suppl 1):21S-28S.
197. Van Ness MM, Diehl
AM: Is liver biopsy useful in the evaluation of patients with chronically
elevated liver enzymes? Ann Intern Med 1989;111:473-478.
198. Alter HJ, Conry-Cantilena
C, Melpolder J, et al.: Hepatitis C in asymptomatic blood donors. Hepatology
1997;26(Suppl 1):29S-33S.
199. Mathurin P, Moussali
J, Cadranel J-F, et al.: Slow progression rate of fibrosis in hepatitis
C patients with persistently normal alanine aminotransferase activity.
Hepatology 1998;27:568-572.
199a. Kenny-Walsh E, for
the Irish Hepatology Research Group: Clinical outcomes after hepatitis
C infection from contaminated anti-D immune globulin. N Engl J Med 1999;340:1228-1233.
200. Marcellin P, Levy
S, Erlinger S: Therapy of hepatitis C: patients with normal aminotransferase
levels. Hepatology 1998;26(Suppl 1):133S-136S.
201. San Giovani A, Spinzi
GC, Ceriani R, et al.: Randomized control trial of HCV healthy carriers
with interferon. Hepatology 1995;22:290A.
202. Centers for Disease
Control and Prevention: Recommendations for the prevention and control
of hepatitis C virus (HCV) infection and HCV-related chronic disease.
MMWR 1998;47(No.RR-19), 1-39.
203. Quinn PG, Johnston
DE: Detection of chronic liver disease: costs and benefits. Gastroenterologist
1997;5:58-77.
204. Sampliner RE, Deluk
D, Harrow EJ: Blood donors with elevated alanine aminotransferase levels
– persistence of elevation and liver histology. Gastroenterology 1983;84:1394.
205. Hultcrantz R, Glaumann
H, Lindberg G, Nilsson LH: Liver investigation in 149 asymptomatic patients
with moderately elevated activities of serum aminotransferases. Scand
J Gastroenterol 1986;21:109-113.
206. Friedman LS, Dienstag
JL, Watkins E, et al.: Evaluation of blood donors with elevated serum
alanine aminotransferase levels. Ann Intern Med 1987;107:137-144.
207. Hay JE, Czaja AJ,
Rakela J, Ludwig J: The nature of unexplained chronic aminotransferase
elevations of a mild to moderate degree in asymptomatic patients. Hepatology
1989;9:193-197.
208. Kundrotas LW, Clement
DJ: Serum alanine aminotransferase (ALT) elevation in asymptomatic US
Air Force basic trainee blood donors. Dig Dis Sci 1993;38:2145-2150.
209. Serafty L, Nousbaum
JB, Elghouzzi MH, Giral P, Legendre C, Poupon R: Prevalence, severity,
and risk factors of liver disease in blood donors positive in a second-generation
anti-hepatitis C virus screening test. Hepatology 1995;21:725-729.
210. Cauza E, Maier-Dobersberger
T, Polli C, Kaserer K, Kramer L, Ferenci P: Screening for Wilson’s disease
in patients with liver diseases by serum ceruloplasmin. J Hepatol 1997;27:358-362.
211. Adler M, Schaffner
F: Fatty liver hepatitis and cirrhosis in obese patients. Am J Med 1979;67:811-816.
212. Ludwig J, Viggiano
TR, McGill DB, Ott BJ: Nonalcoholic steatohepatitis: Mayo clinic experiences
with a hitherto unnamed disease. Mayo Clin Proc 1980;55:434-438.
213. Sheth SG, Gordon FD,
Chopra S: Nonalcoholic steatohepatitis. Ann Intern Med 1997;126:137-145.
214. Bacon BR, Farahvash
MJ, Janney CJ, Neuschwander-Tetri BA: Nonalcoholic steatohepatitis:
an expanded clinical entity. Gastroenterology 1994;107:1103-1109.
214a. Sorbi D, Boynton
J, Lindor KD: The ratio of aspartate aminotransferase to alanine aminotransferase:
potential value in differentiating nonalcoholic steatohepatitis from
alcoholic liver disease. Am J Gastroenterol 1999;94:1018-1022.
215. Cortez Pinto H, Baptista
A, Camilo MA, Valenta A, Saragoca A, Sarneiro de Moura M: Nonalcoholic
steatohepatitis: clinicopathological comparison with alcoholic hepatitis
in ambulatory and hospitalized patients. Dig Dis Sci 1996;41:172-179.
215a. Palmer M, Schaffner
F: Effect of weight reduction on hepatic abnormalities in overweight
patients. Gastroenterology 1990;99:1408-1413.
216. McLaren CE, Gordeuk
VR, Looker AC, et al.: Prevalence of heterozygotes for hemochromatosis
in the white population of the United States. Blood 1995;86:2021-2027.
217. Feder JN, Gnirke A,
Thomas W, et al.: A novel MHC class I-like gene is mutated in patients
with hereditary haemochromatosis. Nat Genet 1996;13:399-408.
218. Crawford DH, Jazwinska
EC, Cullen LM, Powell LW: Expression of HLA-linked hemochromatosis in
subjects homozygous or heterozygous for the C282Y mutation. Gastroenterology
1998;114:1003-1008.
219. Milman N, Albeck MJ:
Distinction between homozygous and heterozygous subjects with hereditary
haemochromatosis using iron status markers and receiver operating characteristic
(ROC) analysis. Eur J Clin Chem Clin Biochem 1995;33:95-98.
220. Witte DL: Mild liver
enzyme abnormalities: eliminating hemochromatosis as cause. Cclin Chem
1997;53:1535-1538.
221. McDonnell SM, Phatak
PD, Felitti V, Hover A, McLaren GD: Screening for hemochromatosis in
primary care settings. Ann Intern Med 1998;129:962-970.
222. Bacon BR, Powell LW,
Adams PC, Kresina TF, Hoofnagle JH: Molecular medicine and hemochromatosis:
at the crossroads. Gastroenterology 1999;116:193-207.
223. Bassett ML, Legett
BA, Halliday JW, Webb S, Powell LW: Analysis of the cost of population
screening for haemochromatosis using biochemical and genetic markers.
J Hepatol 1997;27:517-524.
224. Burke W, Thomson E,
Khoury MJ, et al.: Hereditary hemochromatosis – gene discovery and its
implications for population-based screening. JAMA 1998;280:172-178.
225. Cogswell ME, McDonnell
SM, Khoury MJ, Franks AL, Burke W, BrittenhamG: Iron overload, public
health, and genetics: evaluating the evidence for hemochromatosis screening.
Ann Intern Med 1998;129:971-999.
226. Witte DL, Crosby WH,
Edwards CQ, Fairbanks VG, Mitros FA: Practice guideline development
task force of the College of American Pathologists. Hereditary hemochromatosis.
Clin Chim Acta 1996;245:139-200.
227. Adams PC, Gregor JC,
Kertesz AE, Valberg LS: Screening blood donors for hereditary hemochromatosis:
decision analysis model based on a 30-year database. Gastroenterology
1995;109:177-188.
228. Gibbs K, Walshe JM:
A study of the caeruloplasmic concentrations found in 75 patients with
Wilson’s disease, their kindreds, and various control groups. Q J Med
1979;48:447-463.
229. Sass-Korstak A, Bearn
AG: Hereditary disorders of copper metabolism. In Stanbury JB, Wyngaarden
JB, Fredrickson DS (eds): The metabolic basis of inherited disease,
4th Ed. New York: McGraw Hill, 1978, p. 1098-1126.
230. Scheinberg JH, Sternlieb
I: Wilson’s Disease. Philadelphia, W.B. Saunders, 1984, p. 17-24.
231. Dufour J-F, Kaplan
MM: Muddying the water: Wilson’s disease challenges will not soon disappear.
Gastroenterology 1997;113:348-350.
232. Czaja AJ, Carpenter
HA, Manns MP: Antibodies to soluble liver antigen, P450IID5, and mitochondrial
complexes in chronic hepatitis. Gastroenterology 1993;105:1522-1528.
233. Czaja AJ: Autoimmune
hepatitis: evolving concepts and treatment strategies. Dig Dis Sci 1995;40:435-456.
234. Czaja AJ, Magrin S,
Fabiano C, et al.: Hepatitis C virus infection as a deterinant of behavior
in type I autoimmune hepatitis. Dig Dis Sci 1995;40:33-40.
235. Czaja AJ, Taswell
HF, Rakela J, Rabe D: Duration and specificity of antibodies to hepatitis
C virus in chronic active hepatitis. Gastroenterology 1992;102:1675-1679.
236. Carell RW, Jeppson
JQ, Laurell CB: Structure and variation of human alpha-1-antitrypsin.
Nature 1982;298:239-334.
237. Propst T, Propst A,
Dietze O, Judmaier G, Braunsteiner H, Vogel W: Alpha-1-antitrypsin deficiency
and liver disease. Dig Dis 1994;12:139-149.
238. Sveger T: The natural
history of liver disease in alpha-1-antitrypsin deficient children.
Acta Paediatr Scand 1988;77:847-851.
239. Carlson J, Eriksson
S: Chronic ‘cryptogenic’ liver disease and malignant hepatoma in intermediate
alpha1-antitrypsin deficiency identified by a Pi Z-specific
monoclonal antibody. Scand J Gastroenterol 1985;20:835-842.
240. Graziadel IW, Joseph
JJ, Wiesner RH, Therneau TM, Batts KP, Porayko MK: Increased risk of
chronic liver failure in adults with heterozygous a 1-antitrypsin
deficiency. Hepatology 1998;28:1058-1063.
241. Fisher RL, Taylor
L, Sherlock S: a -1-antitrypsin deficiency in liver disease: the
extent of the problem. Gastroenterology 1976;71:646-651.
242. Morin T, Feldman G,
Benhamou JP: Heterozygous alpha1-antitrypsin deficiency and
cirrhosis in adults, a fortuitous association. Lancet 1975;i:250-251.
243. Propst T, Propst A,
Dietze O, Judmaier G, Braunsteiner H, Vogel W.: High prevalence of viral
infection in adults with homozygous and heterozygous alpha1-antitrypsin
deficiency and chronic liver disease. Ann Intern Med 1992;117:641-645.
244. Hodges JR, Millward-Sadler
GH, Baarbatis C, Wright R: Heterozygous MZ alpha1-antitrypsin
deficiency in adults with chronic active hepatitis and cryptogenic cirrhosis.
N Engl J Med 1981;304:557-560.
245. Haber MM, West AB,
Haber AD, Reuben A: Relationship of aminotransferases to liver histological
status in chronic hepatitis C. Am J Gastroenterol 1995;90:1250-1257.
246. Healey CJ, Chapman
RWG, Fleming KA: Liver histology in hepatitis C infection: a comparison
between patients with persistently normal or abnormal transaminases.
Gut 1995;37:274-278.
247. McCormick SE, Goodman
ZD, Maydonovitch CL, Sjogren MH: Evaluation of liver histology, ALT
elevation, and HCV RNA titer in patients with chronic hepatitis C. Am
J Gastroenterol 1996;91:1516-1522.
248. Perrillo RP: The role
of liver biopsy in hepatitis C. Hepatology 1997;26(Suppl 1):57S-61S.
248a. Pontisso P, Bellati
G, Brunetto M, Et al.: Hepatitis C virus profiles in chronically infected
individuals: do they relate to disease activity? Hepatology 1999;29:585-589.
248b. Camma C, Giunta M,
Pinzello G, Morabito A, Verderio P, Pagliaro L: Chronic hepatitis C
and interferon alpha: conventional and cumulative meta-analyses of randomized
clinical trials. Am J Gastroenterol 1999;94:581-595.
249. Hayashi PH, Beames
MP, Kuhns MC, Hoofnagle JH, Di Bisceglie AM: Use of quantitative assays
for hepatitis B e antigen and IgM antibody to hepatitis B core antigen
to monitor therapy in chronic hepatitis B. Am J Gastroenterol 1996;91:2323-2328.
250. Heijtink RA, Kruining
J, Honkoop P, et al.: Serum HBeAg quantitation during antiviral therapy
for chronic hepatitis B. J Med Virol 1997;53:282-287.
251. Bernard F, Raymond
G, Willems B, Villeneuve JP: Quantitative assessment of serum hepatitis
B e antigen, IgM hepatitis B core antibody and HBV DNA in monitoring
the response to treatment in patients with chronic hepatitis B. J Viral
Hepat 1997;4:265-272.
252. Pawlotsky JM, Batiste
A, Lonjon I, et al.: What technique should be used for routine detection
and quantification of HBV DNA in clinical samples. J Virol Methods 1997;65:245-253.
253. Management of Hepatitis
C. NIH Consens Statement 1997;15:1-41.
254. Davis GL, Lau JYN:
Factors predictive of a beneficial response to therapy of hepatitis
C. Hepatology 1997;26(Suppl 1):122S-127S.
255. Davis GL, Balart LA,
Schiff ER, et al.: Treatment of chronic hepatitis C with recombinant
interferon alfa: a multicenter randomized controlled trial. N Engl J
Med 1989;321:1501-1506.
256. Lindsay KL, Davis
GL, Schiff ER, et al.: Response to higher doses of interferon alfa-2b
in patients with chronic hepatitis C: a randomized multicenter trial.
Hepatology 1996;24:1034-1040.
257. Kasahara A, Hayashi
N, Mochizuki M, et al.: Risk factors for hepatocellular carcinoma and
its incidence after interferon treatment in patients with chronic hepatitis
C. Hepatology 1998;27:1394-1402.
258. McHutchison JG, Gordon
SC, Schiff ER, et al.: Interferon alfa-2b or in combination with ribavirin
as initial treatment for chronic hepatitis C. N Engl J Med 1998;339:1485-1492.
259. Poynard T, Marcellin
S, Lee SS, et al.: Randomised trial of interferon alpha2b plus ribavirin
for 48 weeks or for 24 weeks versus interferon alpha2b plus placebo
for 48 weeks for treatment of chronic infection with hepatitis C virus.
International Hepatitis Interventional Therapy Group (IHIT). Lancet
1998;352:1426-1432.
260. Nagayama Y, Ohta K,
Tsuruta M, et al.: Exacerbation of thyroid autoimmunity by interferon
a treatment in patients with chronic viral hepatitis: our studies
and review of the literature. Endocr J 1994;41:565-572.
261. Davis BH, Kresina
TF: Hepatic Fibrogenesis. Clin Lab Med 1996;16:361-375.
262. Oberti F, Valsesia
E, Pilette C, et al.: Noninvasive diagnosis of hepatic fibrosis or cirrhosis.
Gastroenterology 1997;113:1609-1616.
263. Kropf J, Gressner
AM, Negwer A: Efficacy of serum laminin measurement for diagnosis of
fibrotic liver diseases. Clin Chem 1988;34:2026-2030.
264. Tsutsumi M, Takase
S, Urashima S, Ueshima Y, Kawahara H, Takada A: Serum markers for hepatic
fibrosis in alcoholic liver disease: which is the best marker, type
III procollagen, type IV collagen, laminin, tissue inhibitor of metalloproteinase,
or prolyl hydroxylase. Alcohol Clin Exp Res 1996;20:1512-1517.
265. Yamada S, Suou T,
Kawasaki H, Yoshikawa N: Clinical significance of serum 7S collagen
in various liver diseases. Clin Biochem 1992;25:467-470.
266. Guechot J, Laudat
A, Loria A, Serfaty L, Poupon R, Giboudeau J: Diagnostic accuracy of
hyaluronan and type III procollagen amino-terminal peptide serum assays
as markers of liver fibrosis in chronic viral hepatitis C evaluated
by ROC curve analysis. Clin Chem 1996;42:558-563.
267. Korner T, Kropf J,
Gressner AM: Serum laminin and hyaluronan in liver cirrhosis: markers
with high prognostic value. J Hepatol 1996;25:684-688.
268. Fabris C, Falleti
E, Federico E, Toniutto P, Pirisi M: A comparison of four serum markers
of fibrosis in the diagnosis of cirrhosis. Ann Clin Biochem 1997;34:151-155.
269. Sopena B, Martinez-Vazquez
C, Fernandez-Rodriguez CM, et al.: Serum angiotensin converting enzyme
and C4 protein of complement as a combined diagnostic index in alcoholic
liver disease. Liver 1996;16:305-308.
270. Falleti E, Pirisi
M, Gabris C, et al.: Circulating standard CDP9D isoform in patients
with liver disease: relationship with other soluble adhesion molecules
and evaluation of diagnostic usefulness. Clin Biochem 1997;30:69-73.
271. Trinchet J-C: Clinical
use of serum markers of fibrosis in chronic hepatitis. J Hepatol 1995;22(Suppl
2):89-95.
272. Williams AL, Hoofnagle
JH: Ratio of serum aspartate to alanine aminotransferase in chronic
hepatitis. Relationship to cirrhosis. Gastroenterology 1988;95:734-739.
273. Sheth SG, Glamm SL,
Gordon FD, Chopra S: AST/ALT ratio predicts cirrhosis in patients with
chronic hepatitis C virus infection. Am J Gastroneterol 1998;93:44-48.
273a. Goldstein NS, Blue
DE, Hankin R, et al.: Serum a -fetoprotein levels in patients with
chronic hepatitis C – relationship with serum alanine aminotransferase
values, histologic activity index, and hepatocyte MIB-1 scores. Am J
Clin Pathol 1999;111:811-816.
273b. Bayati N, Silverman
AL, Gordon SC: Serum alpha-fetoprotein levels and liver histology in
patients with chronic hepatitis C. Am J Gastroenterol 1998;93:2452-2456.
274. El-Serag HB, Mason
AC: Rising incidence of hepatocellular carcinoma in the United States.
N Engl J Med 1999;340:745-750.
275. Fattovich F, Giustina
G, Schalm SW, et al..: Occurrence of hepatocellular carcinoma and decompensation
in western European patients with cirrhosis type B. Hepatology 1995;21:77-82.
276. Fattovich G, Giustina
G, Degos F, et al.: Morbidity and mortality in compensated cirrhosis
type C: a restrospective follow-up study of 384 patients. Gastroenterology
1997;112:463-472.
277. Zaman SN, Johnson
PJ, Williams R: Silent cirrhosis in patients with hepatocellular carcinoma.
Implications for screening in high-incidence and low-incidence areas.
Cancer 1990;65:1607-1610.
278. McMahon BJ, London
T: Workshop on screening for hepatocellular carcinoma. J Natl Cancer
Inst 1991;83:916-919.
279. Riegler JL: Preneoplastic
conditions of the liver. Sem Gastrointest Dis 1996;7:74-87.
280. Pateron D, Ganne N,
Trinchet JC, et al.: Prospective study of screening for hepatocellular
carcinoma in Caucasian patients with cirrhosis. J Hepatol 1995;22:708-709.
281. Sherman M, Peltekian
KM, Lee C: Screening for hepatocellular carcinoma in chronic carriers
of hepatitis B virus: incidence and prevalence of hepatocellular carcinoma
in a North American population. Hepatology 1995;22:432-438.
282. Villeneuve J-P, Desrochers
M, Infante-Rivard C, et al.: A long-term follow-up study of asymptomatic
hepatitis B surface antigne-positive carriers in Montreal. Gastroenterology
1994;108:1000-1005.
283. Colombo M, de Franchis
R, Del Ninno E, et al.: Hepatocellular carcinoma in Italian patients
with cirrhosis. N Engl J Med 1991;325:675-680.
284. Mazzaferro V, Regalia
E, Doci R, et al.: Liver transplantation for the treatment of small
hepatocellular carcinomas in patients with cirrhosis. N Engl J Med 1996;334:693-699.
285. Cottone M, Turri M,
Caltagirone M, et al.: Screening for hepatocellular carcinoma in patients
with Child’s A cirrhosis: an 8 year prospective study by ultrasound
and alphafetoprotein. J Hepatol 1994;21:1029-1034.
286. Oka H, Tamori A, Kuroki
T, Kobayashi K, Yamamoto S: Prospective study of alpha-fetoprotein in
cirrhotic patients monitored for development of hepatocellular carcinoma.
Hepatology 1994;19:61-66.
287. Sarasin FP, Giostra
E, Hadengue A: Cost-effectiveness of screening for detection of small
hepatocellular carcinoma in western patients with Child-Pugh class A
cirrhosis. Am J Med 1996;101:422-434.
288. Collier J, Sherman
M: Screening for hepatocellular carcinoma. Hepatology 1998;27:273-278.
289. Sheu JC, Sung JL,
Chen DS, et al.: Growth rate of asymptomatic hepatocellular carcinoma
and its clinical significance. Gastroenterology 1983;89:259-266.
290. Cottone M, Virdone
R, Fusco G, et al.: Asymptomatic hepatocellular carcinoma in Child’s
A cirrhosis. Gastroenterology 1989;96:1566-1571.
291. Barbara L, Benzi G,
Gaiani S, et al.: Natural history of small untreated hepatocellular
carcinoma in cirrhosis: a multivariate analysis of prognostic factors
of tumor growth rate and patient survival. Hepatology 1992;16:132-137.
292. Fujiyama S, Morishita
T, Hashiguchi O, Sato T: Plasma abnormal prothrombin (des-g -carboxy
prothrombin) as a marker of hepatocellular carcinoma. Cancer 1988;61:1621-1628.
293. Liebman HA, Furie
BC, Tong MJ, et al.: Des-g -carboxy (abnormal) prothrombin as a
serum marker of primary hepatocellular carcinoma. N Engl J Med 1984;310:1427-1431.
294. Aoyagi Y, Oguro M,
Yanagi M, et al.: Clinical significance of simultaneous determinations
of alpha-fetoprotein and des-gamma-carboxy prothrombin in monitoring
recurrence in patients with hepatocellular carcinoma. Cancer 1996;77:1782-1796.
295. Izuno K, Fujiyama
S, Yamasaki K, Sato M, Sato T: Early detection of hepatocellular carcinoma
associated with cirrhosis by combined assay of des-gamma-carboxy prothrombin
and alpha-fetoprotein: a prospective study. Hepatogastroenterology 1995;42:387-393.
296. Mita Y, Aoyagi Y,
Yanagi M, Suda T, Suzuki Y, Asakura H: The usefulness of determining
des-gamma-carboxy prothrombin by sensitive enzyme immunoassay in the
early diagnosis of patients with hepatocellular carcinoma. Cancer 1998;82:1643-1648.
297. Lefrere J-J, Gozin
D, Soulier J-P, et al.: Specificity of increased des-gamma-carboxyprothrombin
in hepatocellular carcinoma after vitamin K1 injection. J Hepatol 1987;5:27-29.
298. Sakon M, Monden M,
Gotoh M, et al.: The effects of vitamin K on the generation of des-g
-carboxy prothrombin in patients with hepatocellular carcinoma. Am J
Gastroenterol 1991;86:339-345.
298a. Nomura F, Ishijima
M, Kuwa K, Tanaka N, Nakai T, Ohnishi K: Serum des-gamma-carboxy prothrombin
levels determined by a new generation of sensitive immunoassays in patients
with small-sized hepatocellular carcinoma. Am J Gatroenterol 1999;94:650-654.
299. Shiraki K, Takase
K, Tameda Y, et al.: A clinical study of lectin-reactive alpha-fetoprotein
as an early indicator of hepatocellular carcinoma in the follow-up of
cirrhotic patients. Hepatology 1995;22:802-807.
300. Lu Y, Lu Q, Chen HL:
Diagnosis of primary liver cancer using lectin affinity chromatography
of serum alkaline phosphatase. J Exp Clin Cancer Res 1997;16:75-80.
301. Yao D-F, Huang Z-W,
Chen S-Z, et al.: Diagnosis of hepatocellular carcinoma by quantitative
detection of hepatoma-specifid bands of serum g -glutamyltransferase.
Am J Clin Pathol 1998;110:743-749.
back
|
